With a global footprint, an established on-the-ground presence in Israel and strong relationships with local law firms, our team is well-positioned to represent Israeli companies of all sizes, along with investors looking to acquire or invest in Israeli companies. For years, we have ranked number one in volume of capital markets transactions in Israel, and you can rely on our experience and respected reputation for both inbound and outbound work in capital markets and securities, as well as M&A. We also collaborate with top-ranked colleagues across practices and offices worldwide—including our world-class healthcare practice, as the only law firm to be ranked #1 in healthcare by all the leading industry rankings—to handle any of your most pressing legal needs.
When you hire us, you gain access to a full-service global network of skilled lawyers spanning corporate and M&A, tax, healthcare and life sciences, private equity, litigation, employment and beyond. Many of our lawyers are native Hebrew speakers, and because we do not practice Israeli law, we have developed trusted, longstanding partnerships with local law firms. Our ability to navigate the local language and culture, along with Delaware law and complex securities laws both internationally and in the United States, gives you an edge in securing financing, completing transactions in and outside of Israel, establishing your company’s presence overseas and achieving your other business objectives.
We take a sophisticated and efficient approach to transactions and other matters across a variety of industries, drawing on our long history of counseling Israeli public companies and investment banks in IPOs, follow-on public offering transactions and other corporate and commercial matters. We also help foreign investors, family offices and private equity funds identify and capitalize on opportunities in the region. Above all, we are responsive, attentive and committed to providing outstanding client service.
Galmed Pharmaceuticals Ltd., an Israeli biotech company, in a public offering of 5,000,000 ordinary shares of Galmed. The offering resulted in aggregate net proceeds of $70.5 million after underwriting discounts and commissions but before expenses
CollPlant Holdings Ltd., a biotechnology medical device company, in its Nasdaq listing, multiple PIPE transactions and ongoing securities matters
InterCure, the leading, profitable, and fastest growing cannabis company outside of North America, in its listing on Nasdaq
Verbit, the world’s largest AI-powered transcription platform, as US counsel in its acquisition of VITAC, the largest provider of captioning products and solutions in North America
Pierpoint Capital LLC in the launch of Pierpoint CoreFlow SPV LP, an investment fund backed by several family offices, and the subsequent $11,750,000 investment by Pierpoint CoreFlow SPV LP into CoreFlow, Ltd., an Israeli company that designs and markets aeromechanical manufacturing equipment
Check-Cap Ltd., a clinical-stage medical diagnostics company focusing on the prevention of colorectal cancer, in a registered direct offering of 25,925,926 of its ordinary shares and warrants to purchase up to 25,925,926 ordinary shares, at a combined offering price of $1.35 for each pairing of one share and one warrant to purchase one ordinary share of the company. The total gross proceeds to Check-Cap Ltd. were $35 million
InspireMD, Inc., a medical device company, in its upsized underwritten public offering of 29,032,258 units priced at a public offering price of $0.62 per unit, with each unit consisting of one share of common stock and one Series G warrant to purchase one-half of one share of common stock. The gross proceeds from the offering were approximately $20.7 million
Can-Fite BioPharma Ltd, a dual-listed Israeli biotech company, in multiple registered direct offerings, a warrant repricing, a follow-on offering on Form F-1, defending against a takeover attempt, and ongoing US securities matters
Finnovate Acquisition, a blank check company targeting the fintech sector in Israel, in a $150 million IPO
BioLineRx Ltd., a late clinical-stage biopharmaceutical company focused on oncology, in a bought deal offering of 14,375,000 of its American Depositary Shares (ADSs), at a purchase price of $2.40 per ADS
Moringa Acquisition Corp, a blank check company intended to focus its search on Israel-related technology companies, in its initial public offering of 10 million units at $10.00 per unit for gross proceeds of approximately $100 million
PainReform Ltd., a clinical-stage biopharmaceutical company in its ongoing SEC reporting and Nasdaq compliance
Sapiens International Corporation N.V., a global provider of software solutions for the insurance industry, in a follow-on offering and debt offerings
My Size, Inc., a technology company, in establishment of an ATM program, a registered direct offering, a follow-on offering on Form S-1 and ongoing US securities matters
Cactus Acquisition Corp. 1 Limited, an Israeli SPAC targeting the healthcare sector in Israel, in its $126.5M IPO
H.C. Wainwright & Co. in its role as the sole book-running manager for MeaTech 3D Ltd., a technology company focused on developing and out-licensing its proprietary three-dimensional printing technology, biotechnology processes and customizable manufacturing processes to food processing and food retail companies, in its initial public offering of 2,427,185 American Depositary Shares (ADSs), each ADS representing 10 ordinary shares of MeaTech 3D Ltd., at the initial public offering price of $10.30 per ADS